Loading...

VAXART INC Company Mergers 8-K Filing

VXRT

VAXART INC

()

2025 8-K

Financial Results Update

Lease Termination

Quarterly Financial Update

License Agreement Signed

Stock Delisting Notice

Proposal Withdrawal

Special Meeting Delayed

Nasdaq Listing Continuation

Fireside Chat Report

Management Announcement

Financial Results Announcement

Clinical Trials

Voluntary Delisting

Forced Delisting

Clinical Trials

Adjournment of Meeting

Reverse Stock Split

Product Expansion

New Product Launches

Financial Statements

Reverse Stock Split

Reverse Stock Split

Clinical Trials

Financial Results

Vaccine Trial Announcement

Funding Increase

Clinical Trial Update

Nasdaq Compliance Notice

Funding Increase

Vaccine Trial Update

Q3 Financial Results

Sales Agreement Termination

Funding Increase

Earnings Reports

Amendment to Voting Results

Underwriting Agreement

BARDA Funding Agreement

Amendment and Restatement o...

Earnings Reports

Clinical Trial Completion

Financial Results Announcement

Appointment of CEO

Management Changes

Compliance regained with Na...

Amendment - Separation Agre...

Delisting Notice

Securities Purchase Agreeme...

Contract Award and CEO Resi...

Financial Results Announcement

Disclosure of Say-on-Pay Vo...

Bylaws Amendment

Earnings Reports

Delisting Notice

Annual Meeting of Stockholders

Underwriting Agreement

Press Release Update

Compliance regained with Na...

Earnings Reports

Earnings Reports

External Links:

On November 4, 2025, Vaxart, Inc. entered into a $25 million Exclusive License and Collaboration Agreement with Dynavax Technologies for its COVID-19 vaccine and will sell $5 million of its stock. If Dynavax opts to continue development post-clinical trials, Vaxart could earn up to $195 million in regulatory milestones and $425 million in sales milestones.

AI Assistant

VAXART INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.